1 BTC
=
- USD
Onconetix, Inc. Common Stock
As of May 30, 2026 at 12:32 UTC
Chart
About Onconetix, Inc. Common Stock
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of solutions for men's health and oncology. The company owns Proclarix, an in vitro diagnostic test for prostate cancer, approved for sale in the European Union. Additionally, it is focused on marketing Proclarix in the U.S. as a lab-developed product. Onconetix operates in one segment: commercial. Geographically, the company generates maximum revenue from Switzerland and the rest from the United Kingdom.
Market Statistics
Trading Metrics
How to Buy ONCO
Create Your Account
Sign up, deposit BTC, and transfer it to your Unified Trading Account. It only takes a moment.
Start Your Trade
From Terminal, click Trade Now on the asset you want to buy. You'll be purchasing its tokenized asset.
Buy ONCO
Enter the amount and confirm your purchase. That's it! You'll see the impact of the trade in your Unified Trading Account.
New to Tokenized Assets? Learn more in our Help Center.
Latest News
5 articlesOnconetix Inc. (NASDAQ:ONCO) shares surged 23.65% to $0.38 in after-hours trading on Monday, reversing an 18.26% regular session decline. The biotech company reported clinical validation progress for Proclarix, a blood test for prostate cancer detection, with new peer-reviewed publications and initiation of a U.S. validation trial with Labcorp. However, the stock has dropped 99.11% over the past 12 months and currently trades at its annual low.
Onconetix shares surged 71.74% in premarket trading on Friday following the announcement of its acquisition of Realbotix, a company specializing in AI-driven humanoid robots. The acquisition is expected to enhance Onconetix's capabilities in AI and robotics. Additionally, the company implemented a 1-for-5 reverse stock split effective March 25. Despite the positive premarket movement, the stock remains down 92.97% over the past 12 months and trades near its 52-week low.
Onconetix and Ocuvex Therapeutics have signed a definitive merger agreement where Onconetix will acquire Ocuvex, with Ocuvex shareholders receiving 90% of the combined company's equity. The transaction is expected to close in Q4 and aims to bring ophthalmic therapeutic assets to the public markets.
Onconetix, Inc. announced the closing of the exercise of existing warrants and the issuance of new warrants in a private placement, raising approximately $1.11 million. The company plans to use the proceeds for working capital and general corporate purposes.